Resources from the same session
3410 - METEOR-1: A Phase I Study of GSK3326595, a First-In-Class Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Advanced Solid Tumors
Presenter: Lillian Siu
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
3777 - A first in human, phase 1 trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors.
Presenter: Philippe Cassier
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1621 - Phase 1 Study of the Arginase Inhibitor INCB001158 (1158) Alone and in Combination with Pembrolizumab (PEM) in Patients (Pts) with Advanced/Metastatic (Adv/Met) Solid Tumors
Presenter: Aung Naing
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
441O - A Platform Trial with a Registry Study for Rare Cancers: MASTER KEY Project
Presenter: Shoko Narita
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
2651 - Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study
Presenter: Steffie Groenland
Session: Proffered Paper – Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Proffered Paper – Developmental therapeutics - Invited Discussant 441O and 442O
Presenter: Christophe Le Tourneau
Session: Proffered Paper – Developmental therapeutics
Resources:
Slides
Webcast